Celgene (CELG) shows how growth abroad can make up for weakness at home. In its Q3 report, released Oct. 25, the Summit, N.J.-based biomed reported EPS of $1.29 on sales of $1.42 billion -- up 26% and 14%, respectively. Both gauges beat estimates by modest amounts. Celgene also upped its full-year EPS guidance by a nickel. That puts it in a $4.85-$4.90 range, vs. last year's $3.79. Sales of Celgene's bread-and-butter product, cancer treatment